跳至主要内容
临床试验/EUCTR2007-006117-16-GB
EUCTR2007-006117-16-GB进行中(未招募)1 期

A prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (BuTrans 20µg/h) matrix transdermal patch in the management of post tonsillectomy pain in adults - PATCH Trial

Betsi Cadwaladr University Health Board0 个研究点目标入组 300 人开始时间: 2007年11月26日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Patients undergoing tonsillectomy, which meet the following criteria:
  • aged 18 to 50 years old;
  • ASA grade I & II - healthy patient; mild systemic disease with no functional limitation (e.g. well controlled HTA)
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • age less than 18 or over 50;
  • ASA grade III - severe systemic disease with definite functional limitation e.g. unstable angina)
  • conditions in which the respiratory centre and function are severely impaired or may become so;
  • asthmatic and allergic to NSAIDS;
  • hypotension
  • pregnancy and lactation;
  • recent head injury;
  • known hypersensitivity towards the active substance buprenorphine or to any of the excipients (for the excipients see section 6.1);
  • in opioid-dependent patients and for narcotic withdrawal treatment;
  • patients who are receiving MAO inhibitors or have taken them within the last two weeks;
  • patients suffering from myasthenia gravis;
  • patients suffering from delirium tremens or acute alcohol intoxication;
  • convulsive disorders

研究者

相似试验

A prospective, randomised, phase IV, open label... | 临床试验